- US-based biotech firm Kure Cells raised USD 10M in Series A funding led by Saudi investor Wa’ed Ventures.
- The round included Qomel Co, NantBio, and US93 Group, supporting Saudi Arabia’s biotech and advanced therapy ambitions.
- Kure Cells plans to expand into Saudi Arabia, establishing R&D and manufacturing sites for its rapid UF-CAR cell therapy.
Wa’ed Ventures
US-based biotech company, Kure cells secured USD 10 million in a series A funding round led by Wa’ed Ventures. The round also saw participation from Komel Healthcare, U.S. pharmaceutical player NantBio, and several American investors under the US93 group.
Additionally, Saudi’s Qomel Co, also joined the round with a USD 1.38 million in the biotech company. This is in alignment with its strategy to invest in the development of advanced therapeutic products and technologies.
This investment aligns with the Ministry of Investment’s and the Research, Development and Innovation Authority’s ambitions to make the Kingdom a regional hub for biotech advancement.
Biotech
Up next with the funding, it aims to expand its footprint into Saudi through establishing research, development, and manufacturing sites. Moreover, it seeks to work in tandem with local researchers to tailor its “Ultra‑Fast CAR” platform to regional health systems.
Founded by David Wald and Sayer Alfuraydi, Kure Cells is US-based biotechnology company specializing in advanced cell therapies. Its UF‑CAR technology enables same day engineering of patients T-cells in less than 24 hours. This is a drastic difference from the traditional multi-week processes.
“Their rapid cell therapy manufacturing platform compresses timelines, lowers costs, and broadens patient access while actively building Saudi’s biotech ecosystem through local R&D, talent development, and clinical translation,” said Anas Algahtani, Acting CEO of Wa’ed Ventures.
Bottom line: The investment reflects Saudi Arabia’s growing focus on biotechnology and localized research. Thus, Kure Cells’ expansion aligns with the Kingdom’s broader innovation agenda.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.
